Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma

NCT07217717 is registered in ClinicalTrials.gov with SOFIE as lead sponsor.

NCT NCT07217717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07217717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma
Lead sponsor
SOFIE
Phase
Phase 3
Overall status
Recruiting
Start date
December 11, 2025
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma (pdac)